An update from NovoCure (NVCR) is now available.
At NovoCure Limited’s annual general meeting on June 5, 2024, shareholders elected ten directors for a one-year term, with all directors free of undisclosed third-party arrangements. The meeting saw robust participation with nearly 80% of share votes present. Key propositions, including the ratification of the company’s accounting firm, approval of executive compensation, and the 2024 Omnibus Incentive Plan, were all passed. Additionally, shareholders favored an annual “Say on Pay” advisory vote, illustrating active shareholder engagement in the company’s governance and compensation policies.
Find detailed analytics on NVCR stock on TipRanks’ Stock Analysis page.
